Antroquinonol is under clinical development by Golden Biotechnology and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Antroquinonol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Antroquinonol overview

Antroquinonol (Hocena) is under development for the treatment of relapsed acute myeloid leukemia, acute myeloid leukemia, non squamous non small cell lung cancer, metastasis pancreatic cancer, chronic hepatitis B, hepatocellular carcinoma, nonfamilial hypercholesterolemia, mixed hyperlipidemia and Alzheimer's disease. The drug candidate is a small molecule administered orally. It is a new chemical entity (NCE). The drug candidate is a ubiquinone derivate. It is a purified cyclohexenone compound from the extract of Antrodia camphorate. The drug candidate targets farnesyl transferase and down regulates PI3K and mTOR signaling pathways. It was also under development for atopic dermatitis. It was also under development for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with pneumonia.

Golden Biotechnology overview

Golden Biotechnology (Golden Biotech) is a drug discovery and food supplement manufacturing company. The company develops and commercializes drugs and herbal supplements to prevent and treat several cancer diseases. It discovers and develops new drugs for cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases, and infectious diseases from the screening platforms. Golden Biotech offers products under brand names of liverty, zsaino, rasle and umooze. It operates through trial clinical centers for the completion of COVID-19 in the US, Peru, and Argentina. The company markets its products across China, Taiwan, the US, Malaysia, and Japan, among others. Golden Biotech is headquartered in New Taipei, Taiwan.

For a complete picture of Antroquinonol’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.